000			03379nam a22005295i 4500
001			978-94-007-6467-5
003			DE-He213
005			20140220082942.0
007			cr nn 008mamaa
008			130507s2013 ne | s |||| 0|eng d
020			_a9789400764675 _9978-94-007-6467-5
024	7		_a10.1007/978-94-007-6467-5 _2doi
050		4	_aR-RZ
072		7	_aMBGR _2bicssc
072		7	_aMED000000 _2bisacsh
082	0	4	_a610 _223
100	1		_aMousa, Shaker A. _eeditor.
245	1	0	_aAngiogenesis Modulations in Health and Disease _h[electronic resource] : _bPractical Applications of Pro- and Anti-angiogenesis Targets / _cedited by Shaker A. Mousa, Paul J. Davis.
264		1	_aDordrecht : _bSpringer Netherlands : _bImprint: Springer, _c2013.
300			_aX, 206 p. 40 illus., 13 illus. in color. _bonline resource.
336			_atext _btxt _2rdacontent
337			_acomputer _bc _2rdamedia
338			_aonline resource _bcr _2rdacarrier
347			_atext file _bPDF _2rda
505	0		_aPreface -- Angiogenesis assays: an appraisal of current techniques -- Survey of pro-angiogenesis strategies -- Angiogenesis modulation by arachidonic acid – derived lipids: positive and negative regulators of angiogenesis -- Pro-angiogenic activity of thyroid hormone analogues: Mechanisms, physiology and clinical prospects -- Actions of steroids and peptide hormones on angiogenesis -- Role of non-neuronal nicotinic acetylcholine receptors in angiogenesis modulation.-  Catecholamine neurotransmitters: an angiogenic switch in the tumor microenvironment -- Impact of nanotechnology on therapeutic angiogenesis -- Survey of anti-angiogenesis strategies -- Tetraiodothyroacetic acid (tetrac), nanotetrac and anti-Angiogenesis -- Integrin antagonists and angiogenesis -- Anti-angiogenesis therapy as an adjunct to chemotherapy in oncology -- Anti-vegf strategies in ocular angiogenesis- mediated disorders, with special emphasis on age-related macular degeneration -- Application of nanotechnology to targeting tumor angiogenesis for therapeutic benefit -- Biomarkers of response and resistance to anti-angiogenic treatment -- Speculations on new directions in which angiogenesis may proceed. Index.
520			_a This book is a major update of novel targets in angiogenesis modulation, including pro- and anti-angiogenesis. There is in-depth coverage of preclinical and clinical methods and models, investigational status, and clinical applications. The impact of nanotechnology in advancing the applications of pro-and anti-angiogenesis strategies is also highlighted, along with stem cell and biotechnologies in research and development of angiogenesis modulating targets.
650		0	_aMedicine.
650		0	_aNeurosciences.
650		0	_aBiotechnology.
650		0	_aPharmacy.
650		0	_aLife sciences.
650		0	_aCytology.
650	1	4	_aBiomedicine.
650	2	4	_aBiomedicine general.
650	2	4	_aNeurosciences.
650	2	4	_aPharmacy.
650	2	4	_aLife Sciences, general.
650	2	4	_aBiotechnology.
650	2	4	_aCell Biology.
700	1		_aDavis, Paul J. _eeditor.
710	2		_aSpringerLink (Online service)
773	0		_tSpringer eBooks
776	0	8	_iPrinted edition: _z9789400764668
856	4	0	_uhttp://dx.doi.org/10.1007/978-94-007-6467-5
912			_aZDB-2-SBL
999			_c99898 _d99898